TY - JOUR
T1 - Cell Death Induction in Cancer Therapy - Past, Present, and Future
AU - Nonnenmacher, Lisa
AU - Hasslacher, Sebastian
AU - Zimmermann, Julia
AU - Karpel-Massler, Georg
AU - La Ferla-Brühl, Katia
AU - Barry, Sara E
AU - Burster, Timo
AU - Siegelin, Markus D
AU - Brühl, Oliver
AU - Halatsch, Marc-Eric
AU - Debatin, Klaus-Michael
AU - Westhoff, Mike-Andrew
PY - 2016
Y1 - 2016
N2 - The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.
AB - The induction of apoptosis, a physiological type of cell death, is currently the primary therapeutic aim of most cancer therapies. As resistance to apoptosis is an early hallmark of developing cancer, the success of this treatment strategy is already potentially compromised at treatment initiation. In this review, we discuss the tumor in Darwinian terms and describe it as a complex, yet highly unstable, ecosystem. Current therapeutic strategies often focus on directly killing the dominant subclone within the population of mutated cancer cells while ignoring the subclonal complexity within the ecosystem tumor, the complexity of the direct tumor/ microenvironment interaction and the contribution of the ecosystem human - that is, the global environment which provides the tumor with both support and challenges. The Darwinian view opens new possible therapeutic interventions, such as the disruption of the microenvironment by targeting nonmutated cells within the tumor or the interaction points of mutant tumor cells with their environment, and it forces us to reevaluate therapeutic endpoints. It is our belief that a central future challenge of apoptosis-inducing therapies will be to understand better under which preconditions which treatment strategy and which therapeutic endpoint will lead to the highest quality and quantity of a patient's life.
KW - Animals
KW - Antineoplastic Agents
KW - Apoptosis
KW - Humans
KW - Mutation Accumulation
KW - Neoplasms
KW - Tumor Microenvironment
KW - Journal Article
KW - Review
U2 - 10.1615/CritRevOncog.2016016987
DO - 10.1615/CritRevOncog.2016016987
M3 - Review article
C2 - 27915975
SN - 0893-9675
VL - 21
SP - 253
EP - 267
JO - Critical Reviews in Oncogenesis
JF - Critical Reviews in Oncogenesis
IS - 3-4
ER -